Pegylated liposomal doxorubicin (PLD) is one of the standard chemotherapy drugs used to treat ovarian, fallopian tube, or primary peritoneal cancer. The purpose of this study is to see if adding the investigational drug VTX-2337 to PLD therapy is more effective than PLD alone in women with ovarian, fallopian tube, or primary peritoneal cancer that has returned or persists despite prior therapy.
VTX-2337, which is given as a subcutaneous (under the skin) injection, stimulates the immune system and may help the body kill cancer cells. PLD is given intravenously (by vein). Patients in this study will be randomly assigned to receive PLD plus VTX-2337 or PLD with a placebo injection. This study is being conducted by the Gynecologic Oncology Group.